PAVmed Reports Q1 2026 Net Loss of $7M, Issues Going Concern Warning Amidst Dilutive Financing
PAVM is trading near its 52-week low of $6 (11% above the low).
Summary
PAVmed Inc. reported a substantial Q1 2026 net loss and issued a going concern warning, highlighting its reliance on dilutive and costly financing despite increasing cash reserves.
Key Events · Earnings and Guidance · PAVM
-
Going Concern Warning Issued
Management expressed substantial doubt about the company's ability to continue as a going concern within one year due to recurring losses and negative operating cash flows.
-
Significant Net Loss Reported
The company reported a net loss attributable to common stockholders of $7.0 million for Q1 2026, a substantial reversal from a $17.7 million net income in Q1 2025.
-
Dilutive Series D Preferred Stock Offering and Conversion
PAVmed completed a $30 million Series D Preferred Stock offering (net $29.9 million) in February 2026, which converted into 4,615,393 common shares in March 2026 after shareholder approval.
-
Costly Debt Refinancing
Concurrent with the Series D offering, the company refinanced an $8.4 million Senior Secured Convertible Note with a new $15 million note at a 15% interest rate, resulting in a $3.4 million debt extinguishment loss.
Analysis · PAVM · Industrial Applications And Services
PAVmed Inc. reported a significant net loss of $7.0 million for Q1 2026, a sharp decline from a net income of $17.7 million in the prior year, and explicitly stated substantial doubt about its ability to continue as a going concern. While the company increased its cash position to $6.5 million through a $30 million Series D Preferred Stock offering and debt refinancing, these capital raises were highly dilutive and costly, including a new $15 million note at 15% interest and a $3.4 million debt extinguishment loss. The company continues to rely on dilutive financing to fund operations, which used $2.6 million in cash during the quarter. Additionally, significant restricted stock awards totaling $8.8 million were granted to directors and officers post-quarter, further increasing potential dilution.
At the time of this filing, PAVM was trading at $6.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $41.2M. The 52-week trading range was $6.00 to $28.44. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.